/

ROP.SW

ROCHE PSOpen

366.00+6.00 +1.67%CHF

Swiss · as of Oct 13, 05:23 ET · 15m delay

Open

364.30

Prev close

360.00

Day range

364.20367.60

52-week range

258.20375.80

Volume

146.44K0.16×

Mkt cap

291.62B

P/E ttm

24.02

Fwd P/E

16.70

EPS ttm

15.24

Div yield

2.72%

Earnings

—

From 52w high

−2.61%

Price Chart

Yahoo Finance · delayed

ROP.SWOct 13, 2026O 364.30H 367.60L 364.20C 366.00+8.20 (+2.29%)Vol 146.44K

SMA 50359.06
SMA 200340.31

1Y change +26.12% since Oct 10, 2025 close538 bars loadedTimes in Europe/ZurichDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

ROP.SW ROCHE PS · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: +4.63%
1 month: +6.33%
3 months: +11.93%
6 months: +15.06%
Year to date: +11.52%
1 year: +26.16%

Valuation & ownership

Market cap: 291.62B
Enterprise value: 314.43B
P/E (ttm): 24.02
Forward P/E: 16.70
PEG ratio: 1.63
Price / book: 8.92
Price / sales (ttm): 4.63
EV / EBITDA: 13.12
EPS (ttm): 15.24
EPS (forward): 21.91
Beta (5y monthly): 0.33
Dividend yield: 2.72%
Payout ratio: 63.93%
Shares outstanding: 690.07M
Float: 723.68M
Short % of float: —
Short ratio (days): —
Held by insiders: 0.00%
Held by institutions: 44.17%
Avg volume (3m): 899.05K
50-day average: 358.86
200-day average: 339.97
52-week change: +26.16%
S&P 500 52-week: +17.50%

Technicals (daily)

RSI (14): 58.9
vs 50-day SMA: +1.93%
vs 200-day SMA: +7.55%
50 / 200-day trend: ▲ 50 above 200
MACD vs signal: ▲ above
ATR (14) % of price: 2.22%
Realised vol (20d, ann.): 21.2%
From 52-week high: −2.61%
From 52-week low: +41.75%

ANR

Analyst Consensus

19 analysts

Consensus

Buy

2.42 on a 1 (strong buy) – 5 (sell) scale

Mean target

377.24

+3.07% implied

Low 250.00Median 381.00High 434.50

Recommendation trend

Now10 / 7 / 2
1m ago

DES

About ROCHE PS

Yahoo Finance profile

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and others; diagnostic instruments; and digital health solutions. Roche Holding AG has a collaboration agreement with Excalipoint Therapeutics to evaluate EXP011 in DLL3-expressing solid tumors. The company was founded in 1896 and is based in Basel, Switzerland.

Sector: Healthcare
Industry: Drug Manufacturers - General
Headquarters: Basel, Switzerland
Website: roche.com
Officers: Dr. Severin Schwan Ph.D. Executive Chairman
Dr. Thomas Schinecker Group Chief Executive Officer
Dr. Alan Hippe Chief Financial Officer
Ms. Wafaa Mamilli Chief Digital & Technology Officer

SEAS

Seasonality · ROP.SW

2007–2026 · monthly returns

Strongest month Nov +1.85%Weakest month Feb −0.78%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	6.9	4.6	-14.3	1.2	3.4	1.1	6.3	-0.2	-1.0	4.8			+11.5%
2025	11.9	4.6	-2.9	-7.3	-1.4	-2.7	-0.5	1.2	-0.2	-0.4	18.7	6.8	+28.5%
2024	1.1	-6.1	-1.0	-4.0	4.7	8.0	14.5	0.5	-5.8	-1.0	-4.6	0.0	+4.5%
2023	-1.8	-4.7	-4.0	7.4	2.8	-5.1	-1.1	-3.8	-3.8	-6.6	0.9	3.6	−15.8%
2022	-5.9	-2.0	4.7	-1.1	-9.9	-2.4	-1.0	0.0	2.6	2.8	-7.4	-5.6	−23.4%
2021	-0.6	-3.0	2.5	-2.6	5.1	11.5	0.5	5.0	-7.0	3.5	1.6	5.4	+22.7%
2020	3.3	-4.5	1.4	6.8	-0.8	-1.3	-3.7	-0.1	-0.2	-6.5	1.5	3.3	−1.6%
2019	8.4	5.1	-1.5	-1.7	-2.0	4.4	-2.9	1.5	7.3	2.2	3.8	1.9	+29.0%
2018	-6.9	-4.4	-0.1	0.8	-4.4	4.5	10.2	-0.9	-1.3	3.1	5.7	-6.1	−1.3%
2017	0.2	5.0	4.5	1.8	2.1	-8.1	0.3	-0.6	1.5	-6.8	7.7	-0.7	+6.0%
2016	-4.5	-2.6	-7.9	2.5	7.6	-1.8	-3.4	-3.1	0.5	-5.6	-0.4	2.6	−15.8%
2015	-7.9	4.1	3.6	0.5	2.5	-5.1	6.5	-5.4	-2.7	4.4	2.7	0.3	+2.4%
2014	0.0	8.9	-2.4	-2.6	2.1	0.4	0.1	1.1	5.8	0.2	2.0	-6.7	+8.3%
2013	9.5	6.6	2.9	5.2	2.9	-1.7	-3.0	1.8	5.1	3.0	0.6	-1.4	+35.4%
2012	-2.1	1.1	-0.3	5.5	-8.6	7.9	5.9	0.3	1.1	1.9	1.8	0.9	+15.6%
2011	4.8	-2.4	-6.4	6.9	6.9	-6.2	0.6	-0.4	4.3	-1.6	0.2	9.8	+16.2%
2010	0.3	0.5	-4.7	-0.5	-6.7	-6.0	-9.1	1.8	-2.8	7.7	-4.6	-0.6	−23.0%
2009	0.6	-18.6	17.4	-7.5	0.8	1.4	14.1	-0.1	-0.5	-1.7	-0.2	8.3	+9.5%
2008	0.1	4.6	-8.8	-7.5	4.0	2.4	5.6	-4.3	-6.2	1.3	-3.8	-4.4	−16.9%
2007	7.0	-7.0	-1.1	6.1	-1.5	-3.3	-1.3	-2.1	0.5	-6.4	9.1	-9.2	−10.5%

ROP.SW

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

ROP.SW

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About ROCHE PS

Seasonality · ROP.SW

Insider Activity · ROP.SW

Congress Trades · ROP.SW

Congress Trades · ROP.SW

Insider Activity · ROP.SW

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About ROCHE PS

Financial Snapshot

Earnings & Dividends

News

Seasonality · ROP.SW